Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Triphenylchloroethylene

From Wikipedia, the free encyclopedia
Pharmaceutical drug
Pharmaceutical compound
Triphenylchloroethylene
Clinical data
Trade namesGynosone, Oestrogyl
Other namesTPCE; Triphenylchlorethylene; Chlorotriphenylethylene; Phenylstilbene chloride
Drug classNonsteroidal estrogen
Identifiers
  • (1-chloro-2,2-diphenylethenyl)benzene
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC20H15Cl
Molar mass290.79 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3
  • InChI=1S/C20H15Cl/c21-20(18-14-8-3-9-15-18)19(16-10-4-1-5-11-16)17-12-6-2-7-13-17/h1-15H
  • Key:QEQFTTCZLHLKFX-UHFFFAOYSA-N

Triphenylchloroethylene (TPCE; brand namesGynosone,Oestrogyl), ortriphenylchlorethylene, also known aschlorotriphenylethylene or asphenylstilbene chloride, is asyntheticnonsteroidal estrogen of thetriphenylethylene group that was marketed in the 1940s for the treatment ofmenopausalsymptoms,vaginal atrophy,lactation suppression, and all otherestrogen-indicated conditions.[1][2][3]

Theestrogenic effects of triphenylethylene, the parent compound of triphenylchloroethylene, were discovered in 1937.[4] Triphenylchloroethylene was first reported in 1938 and was found to have 20 to 100 times the estrogenic activity of the relatively weak triphenylethylene, a potentiation of effect that was afforded by itshalogensubstituent.[2][5] The drug has a relatively longduration of action when administered viasubcutaneous injection but a duration similar to that ofdiethylstilbestrol orestradiol benzoate when administeredorally.[2][6][7] Along with diethylstilbestrol andtriphenylmethylethylene, triphenylchloroethylene was studied in 1944 bySir Alexander Haddow for the treatment ofbreast cancer and was found to be significantly effective, and this is historically notable in that it was the first time that high-dose estrogens were found to be effective in the treatment of breast cancer.[8][9]

Chlorotrianisene, or tri-p-anisylchloroethylene (TACE), is a potent marketed estrogen and aderivative of triphenylchloroethylene in which each of the threephenyl rings has been substituted with a 4-methoxy group.[5][10]Estrobin, or DBE, is a related, never-marketed estrogen in which there is abromine in place of thechlorine and two of the three phenyl rings haveethoxy groups.[5]Broparestrol, or BDPE is a marketedselective estrogen receptor modulator (SERM) that has a bromine in place of the chlorine of triphenylchloroethylene and a 4-ethyl group on one of the phenyl rings. The SERMclomifene is also a derivative of triphenylchloroethylene.[11]

See also

[edit]

References

[edit]
  1. ^Negwer M, Scharnow HG (2001).Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. pp. 1861–1862.ISBN 978-3-527-30247-5.C20H15Cl 18084-97-4 Chlorotriphenylethene = Triphenylchloroethylene = Phenylstilbene chloride = 1,1',1"-(1-Chloro-1-ethenyl-2-ylidene)tris[benzene] (•) S Gynosone, Oestrogyl, Phenylstilbene chloride U Synthetic estrogen
  2. ^abcEmmens CW (July 1947). "Halogen-substituted oestrogens related to triphenylethylene".The Journal of Endocrinology.5 (3):170–173.doi:10.1677/joe.0.0050170.PMID 20259249.
  3. ^""Gynosone" A New Synthetic Oestrogen". Advertisement.Proc R Soc Med.39 (11). Sep 1946.PMC 2181944.
  4. ^Li JJ (3 April 2009)."Genesis of Statins".Triumph of the Heart: The Story of Statins. Oxford University Press, USA. pp. 33–.ISBN 978-0-19-532357-3.
  5. ^abcSolmssen UV (December 1945). "Synthetic estrogens and the relation between their structure and their activity".Chemical Reviews.37 (3):481–598.doi:10.1021/cr60118a004.PMID 21013428.
  6. ^Jordon VC, Koch R, Lieberman ME (1986)."Structure-Activity Relationships of Nonsteroidal Estrogens and Antiestrogens". In Jordan VC (ed.).Estrogen/antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press. pp. 23–.ISBN 978-0-299-10480-1.
  7. ^Maximov PY, McDaniel RE, Jordan VC (23 July 2013)."Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens".Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 4–.ISBN 978-3-0348-0664-0.
  8. ^Lewis-Wambi J, Jordan VC (27 May 2013)."Diethylstilbestrol: A Tragedy in Reproductive Endocrinology But a Pioneering Cancer Treatment". In Jordan VC (ed.).Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health: Progress and Promise. World Scientific. pp. 42–.ISBN 978-1-84816-959-3.
  9. ^Wagener DJ (13 July 2009)."The history of the hormonal treatment of cancer".The History of Oncology. Bohn Stafleu van Loghum. pp. 189–.ISBN 978-90-313-6143-4.
  10. ^Lisi F (2006)."Adjunctions to Clomiphene Citrate". In Allahbadia G (ed.).Contemporary Perspectives on Assisted Reproductive Technology. Elsevier India. pp. 18–.ISBN 978-81-8147-782-8.
  11. ^Shoham Z, Howles CM (27 June 2012)."Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs and recombinant gonadotropins". In Gardner DK, Weissman A, Howles CM, Shoham Z (eds.).Textbook of Assisted Reproductive Techniques Fourth Edition: Volume 2: Clinical Perspectives. CRC Press. pp. 51–.ISBN 978-1-84184-972-0.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Triphenylchloroethylene&oldid=1296563146"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp